Novartis sues Biocon over patent

|About: Novartis AG (NVS)|By:, SA News Editor

Accusing India drug maker Biocon of infringing on its diabetes drug Galvus patent, Novartis (NVS) goes to Delhi's High Court in an attempt to stop the firm from launching a generic vildagliptin.

The court ruled on March 28 that Biocon cannot proceed until the next court hearing.

India has been a battleground for Big Pharma because local authorities have overruled patents and instituted price cuts in an effort to expand access to medicines. 70% of Indians live on less than $2/day.